Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jinxin Fertility GroupJXFGF 81 EBITDA Margin % is 9.81% as of Dec. 2025, which is 72% below its 10-year median of 34.57. GuruFocus rates JXFGF with a GF Score™ of 81/100 and a GF Value™ of $0.40. The stock has 8 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Jinxin Fertility Group ranks worse than 86.6% on this metric.
Jinxin Fertility Group (OTCPK:JXFGF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Jinxin Fertility Group EBITDA Margin % Related Terms
Jinxin Fertility Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Jinxin Fertility Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JXFGF vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Jinxin Fertility Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jinxin Fertility Group EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Jinxin Fertility Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Jinxin Fertility Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jinxin Fertility Group (JXFGF) has a EBITDA Margin % of 9.81% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jinxin Fertility Group and its competitors. This is 72% below median its historical median of 34.57. According to the industry distribution chart, Jinxin Fertility Group ranks #575 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 86.6%.
Is Jinxin Fertility Group's EBITDA Margin % too high?
Jinxin Fertility Group's current EBITDA Margin % of 9.81% is 72% below median its 10-year median of 34.57. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Jinxin Fertility Group's value of 9.81% is 3.9% below this industry median. Based on the distribution chart, Jinxin Fertility Group ranks #575 out of 664 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Jinxin Fertility Group has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Jinxin Fertility Group's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Jinxin Fertility Group ranks #575 out of 664 companies for EBITDA Margin %. This places Jinxin Fertility Group in the lower half of its industry. The industry median EBITDA Margin % is 10.21. Jinxin Fertility Group's value of 9.81% is 3.9% below this benchmark. While the company's 10-year median is 34.57 vs. the industry median of 10.21, Jinxin Fertility Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jinxin Fertility Group's current EBITDA Margin % of 9.81% is 3.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jinxin Fertility Group and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jinxin Fertility Group's current EBITDA Margin % is 9.81%, which is 72% below median its own 10-year median of 34.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jinxin Fertility Group stock overvalued right now?
Jinxin Fertility Group (JXFGF) has a current EBITDA Margin % of 9.81%. The stock's GF Value™ is $0.40, compared to a current price of $0.29 — trading 27.5% below its estimated fair value. The current EBITDA Margin % is 9.81%, which is 72% below median its 10-year median of 34.57 and 3.9% below the Healthcare Providers & Services industry median of 10.21. Jinxin Fertility Group's overall GF Score™ is 81/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Jinxin Fertility Group (JXFGF), the current EBITDA Margin % is 9.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jinxin Fertility Group (JXFGF) Overvalued in 2026?
Based on GuruFocus' analysis, Jinxin Fertility Group stock appears to be undervalued.
The current stock price of $0.29 is trading 27.5% below its estimated GF Value™ of $0.40.
Key valuation signals for JXFGF:
EBITDA Margin %: 9.81% (72% below median its 10-year median of 34.57)
GF Value™: $0.40 vs. price of $0.29 (27.5% below fair value)
Industry Position: 3.9% below the Healthcare Providers & Services median (#575 of 664)
No single metric tells the full story. See the JXFGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jinxin Fertility Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in providing IVF services in both China and the United States. The firm, through its subsidiary, is engaged in Assisted reproductive services, management services, ambulatory surgery centre facilities services, obstetrics, gynecology & pediatrics medical services, sales of medical consumables and equipment. and ancillary medical services. Geographically, the company generates a majority of its revenue from Greater China, with a small portion of revenue generated from Overseas Business.
81GF Score
Get the complete analysis for JXFGF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JXFGF has been successfully added to your 
